Hikma Outlines Injectables Growth Amid Slow Start For Generics
Generics Revenues Expected To Be Weighted Towards Second Half Of 2022
Hikma has set out its injectables growth expectations after acquiring Custopharm • Source: Christian Horz / Alamy Stock Photo 
